← All trials
NCT04605159
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 16, 2020
- Primary completion
- Aug 1, 2023
- Completion date
- Feb 2, 2024
- First posted
- Oct 27, 2020
- Last posted
- Nov 2, 2020
- Enrollment
- 20000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- GlaxoSmithKlineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.